Construction and Validation of a Prediction Model for Killip Classes II-IV During Hospitalisation in Patients With Acute ST-segment Elevation Myocardial Infarction

构建和验证急性ST段抬高型心肌梗死患者住院期间Killip II-IV级预测模型

阅读:1

Abstract

BACKGROUND: To perform a comprehensive assessment of the predictive value of soluble growth stimulator gene 2 protein (sST2) in predicting in-hospital Killip classes II-IV among patients with acute ST-segment elevation myocardial infarction (STEMI). This study aimed to provide more precise prognostic insights for informed clinical decision-making. METHODS: A retrospective cohort study was performed. The clinical records of STEMI patients admitted to Tianjin TEDA International Cardiovascular Hospital and who received primary percutaneous coronary intervention (PPCI) within 24 hours of symptom onset from July 2021 to March 2023 were analyzed. Statistical methodologies, including univariate and multivariate analyses, were applied to identify potential risk factors associated with the development of in-hospital Killip classes II-IV and to construct a reliable prediction model. RESULTS: Among a total of 232 enrolled STEMI patients, 50 experienced Killip classes II-IV during their hospitalisation. Compared to those with Killip class I, the Killip class II-IV patients presented with significantly elevated sST2 concentrations and a higher heart rate (HR) at the first visit. In contrast, the left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate (eGFR) values in these patients were significantly lower. Multivariate logistic regression analysis revealed that an sST2 level >77.3 ng/mL (odds ratio (OR) = 2.813, 95% confidence interval (CI): 1.201-6.586, p = 0.017), a first-visit HR >94 bpm (OR = 7.286, 95% CI: 2.778-19.106, p < 0.001), an LVEF <50% (OR = 3.336, 95% CI: 1.458-7.631, p = 0.004), and an eGFR <84 mL/(min·1.73 m(2)) (OR = 3.807, 95% CI: 1.556-9.316, p = 0.003) were independent risk factors for the occurrence of in-hospital Killip classes II-IV in STEMI patients treated with PPCI. Receiver operating characteristic (ROC) curve analysis, along with decision curve analysis (DCA), indicated that the combined predictive model integrating sST2, first-visit HR, LVEF, and eGFR exhibited a significantly stronger predictive ability compared to any single parameter. CONCLUSION: In STEMI patients undergoing PPCI, the combination of sST2, first-visit HR, LVEF, and eGFR can effectively predict patients with Killip classes II-IV during hospitalisation, which may contribute to early intervention and improved patient outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。